K Number
K233906
Manufacturer
Date Cleared
2024-02-16

(66 days)

Product Code
Regulation Number
870.2800
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

S-Patch ExL wearable ECG patch is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light headedness, pre-syncope, fatigue, chest pain and/or anxiety. S-Patch ExL wearable ECG patch is intended for use by patients 18 years or older.

Device Description

The S-Patch ExL ECG Patch System ("S-Patch ExL") is a light-weight electrocardiogram ("ECG") data collection device. The S-Patch ExL operates wirelessly, and due to its compact size, it is unobtrusive during daily activity. The S-Patch ExL continuously acquires ECG signals and wirelessly transmits the data and via a smartphone application (that meets the definition of MDDS) to a compatible 3rd-party cloud-based ECG viewing platform for further analysis and interpretation by qualified medical professionals. The S-Patch ExL does not include but works with 3rd-party lithium coin batteries and 3rd-party ECG electrodes.

AI/ML Overview

I am sorry, but the provided text does not contain detailed information about acceptance criteria and the specific study that proves the device meets those criteria. The document is primarily a 510(k) summary for the S-Patch ExL ECG Patch System, focusing on demonstrating substantial equivalence to a predicate device (S-Patch ExL).

While it mentions performance data, it primarily refers to verification and validation activities that "established the safety and performance characteristics of the proposed subject device with respect to the predicate device." It also states that "The following performance data demonstrated conformance with special controls and substantial equivalence to predicate device's performance."

However, it does not list specific acceptance criteria in a table or describe a detailed study designed to meet those criteria. Instead, it lists the types of tests performed to demonstrate safety and performance in comparison to the predicate, such as:

  • Biocompatibility Testing
  • Device Reuse and Cleaning Validation
  • Electrical Safety and Electromagnetic Compatibility (EMC) (compliance with standards like IEC 60601-1, IEC 60601-1-2, IEC 60601-1-11)
  • Firmware/Software Verification and Validation Testing (states no additional testing was required as it uses the same firmware as the predicate)
  • Integration and System Performance Testing (states no additional testing was required as it uses the same firmware as the predicate)
  • Cybersecurity Assessment and Testing (states no additional testing was required as it uses the same firmware as the predicate)
  • Human Factors Usability Validation Study (conducted according to FDA guidance)

Crucially, the document explicitly states:

  • Animal Study: "Animal performance testing was not required for this device."
  • Clinical Study: "Clinical study was not required for demonstrating safety, effectiveness of the subject device and significant equivalence to the predicate device."

Therefore, I cannot provide the requested table of acceptance criteria and reported device performance, nor can I answer the questions about sample size, data provenance, expert qualifications, adjudication methods, MRMC studies, standalone performance, or ground truth for a clinical study, as such a study was not deemed necessary for this 510(k) submission. The performance demonstration relied on showing equivalence to the predicate device through non-clinical testing and shared firmware/software.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

February 16, 2024

Wellysis Corp. Sam Engelman Senior Manager, Digital Health Regulatory Affairs 8F, 425 Teheran-ro, Gangnam-gu Seoul, 06159 South Korea

Re: K233906

Trade/Device Name: S-Patch (S-Patch ExL) Regulation Number: 21 CFR 870.2800 Regulation Name: Medical Magnetic Tape Recorder Regulatory Class: Class II Product Code: MWJ Dated: January 19, 2024 Received: January 19, 2024

Dear Sam Engelman:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

{2}------------------------------------------------

Sincerely,

Jennifer W. Shih -S

Jennifer Shih Kozen Assistant Director Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

510(k) Number (if known) K233906

Device Name S-Patch (S-Patch ExL)

Indications for Use (Describe)

S-Patch ExL wearable ECG patch is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light headedness, pre-syncope, fatigue, chest pain and/or anxiety. S-Patch ExL wearable ECG patch is intended for use by patients 18 years or older.

Type of Use (Select one or both, as applicable)
---------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) Summary

1. Date Prepared

November 17, 2023

2. Submitter's Information

  • Name of Manufacturer: Wellysis Corp.
  • Address: 8F, 425 Teheran-ro, Gangnam-gu, Seoul, Republic of Korea
  • Contact Name: DoGyun Im
  • Telephone No.: +82 10-9140-8475
  • Email Address: Ian.Im@wellysis.com

3. Trade Name, Common Name, Classification

510(k) NumberK233906
Trade/Device/Model NameS-Patch ExL
Product NameS-Patch ExL ECG Patch System
Device Classification NameElectrocardiograph, Ambulatory (Without Analysis)
Regulation Number21 CFR 870.2800
Classification Product CodeMWJ
Device ClassII
510(k) Review PanelCardiovascular

4. Identification of Predicate Device(s)

The identified predicate device within this submission is shown as following:

Predicate Device

510(k) NumberK231289
Trade/Device/Model NameS-Patch Ex
Device Classification NameMedical magnetic tape recorder
Regulation Number21 CFR 870.2800

{5}------------------------------------------------

Classification Product CodeDSH
Device ClassII
510(k) Review PanelCardiovascular

5. Description of the Device

The S-Patch ExL ECG Patch System ("S-Patch ExL") is a light-weight electrocardiogram ("ECG") data collection device.

The S-Patch ExL operates wirelessly, and due to its compact size, it is unobtrusive during daily activity. The S-Patch ExL continuously acquires ECG signals and wirelessly transmits the data and via a smartphone application (that meets the definition of MDDS) to a compatible 3rd-party cloud-based ECG viewing platform for further analysis and interpretation by qualified medical professionals. The S-Patch ExL does not include but works with 3rd-party lithium coin batteries and 3rd-party ECG electrodes.

The S-Patch ExL is intended to be used by medical professionals in accordance with the User Manual. The S-Patch ExL can be worn by a patient in either a healthcare setting or at home. Certain actions (such as replacement of the electrodes) can be performed by the patient at the direction of a medical professional and in accordance with the User Manual.

The S-Patch ExL should be worn continuously with the same electrodes for no more than 72 hours. At 72 hours, the existing electrodes should be removed and exchanged for new electrodes before continuing to collect ECG data.

6. Indications for use

S-Patch ExL wearable ECG patch is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light headedness, pre-syncope, fatigue, chest pain and/or anxiety. S-Patch ExL wearable ECG patch is intended for use by patients 18 years or older.

7. Intended use

The S-Patch ExL wearable ECG patch is an electrocardiography (ECG) data recording device for use by healthcare professionals for continuous collection of the ECG data at home and in healthcare settings.

{6}------------------------------------------------

The data recorded by the S-Patch ExL wearable ECG patch can be uploaded wirelessly via a smartphone application to a compatible 3rd-party cloud-based ECG viewing platform for further analysis and interpretation by qualified clinicians.

The S-Patch ExL wearable ECG Patch does not include automated ECG analysis and is not intended to be used with 3rd party automated ECG analysis software.

    1. Comparison of the Technological Characteristics with the Predicate Devices
      In comparison to the predicate device, the subject device provides similar indications for use, functions and technological characteristics and device performance. A tabular highlevel comparison of the subject device and the predicate device is provided in table below. The S-Patch ExL ECG Patch System is substantially equivalent to its predicate device.
Predicate DeviceSubject Device
K NumberK231289K233906
ManufacturerWellysis Corp.Wellysis Corp.
Product NameS-Patch Ex ECG PatchSystemS-Patch ExL ECG PatchSystem
Review PanelCardiovascularCardiovascular
Regulation Number21 CFR 870.280021 CFR 870.2800
Product CodeDSHMWJ
Indications for UseS-Patch Ex wearable ECGpatch is indicated for use onpatients who may beasymptomatic or who maysuffer from transientsymptoms such aspalpitations, shortness ofbreath, dizziness, lightheadedness, pre-syncope,syncope, fatigue, chest painand/or anxiety. S-Patch Exwearable ECG patch isintended for use by patients18 years or older.S-Patch ExL wearable ECGpatch is indicated for use onpatients who may beasymptomatic or who maysuffer from transientsymptoms such aspalpitations, shortness ofbreath, dizziness, lightheadedness, pre-syncope,syncope, fatigue, chest painand/or anxiety. S-Patch ExLwearable ECG patch isintended for use by patients18 years or older.
Intended PatientPopulationGeneral care patients whoare 18 years or olderGeneral care patients whoare 18 years or older
Single UseS-Patch Ex is multi-patient,multi-use; compatible 3rd-party ECG electrode is singleuseS-Patch ExL is multi-patient,multi-use; compatible 3rd-party ECG electrode is singleuse

{7}------------------------------------------------

Predicate DeviceSubject Device
Intended UseEnvironmentHome & Healthcare settingsHome & Healthcare settings
MeasuredParametersECG××
ECG Dynamic Range-10mV to + 10mV-10mV to + 10mV
Applied Part CategoryType CF (cardiac floating)Type CF (cardiac floating)
BatteryDC 3V, Coin Battery(CR2032) - 100 hoursDC 3V, Coin Battery(CR2450) - 216 hours
Data Storage andTransfer××
CommunicationProtocolBluetooth Low Energy (2402 – 2480 MHz)Bluetooth Low Energy (2402 – 2480 MHz)
Viewing SoftwarePlatformA compatible 3rd-party ECGviewing softwareA compatible 3rd-party ECGviewing software
Data EncryptionAdvanced EncryptionStandard-CCM modeAdvanced EncryptionStandard-CCM mode
Battery SideEnclosure Size30mm × 6mm35.6mm × 8.7 mm
Weight9 g11 g

9. Performance Data

Verification and validation activities established the safety and performance characteristics of the proposed subject device with respect to the predicate device. The following performance data demonstrated conformance with special controls and substantial equivalence to predicate device's performance.

Biocompatibility Testing

Biocompatibility testing was conducted, included in-vitro cytotoxicity, irritation and sensitization, according to the recommendations of ISO 10993-1:2009, Biological evaluation of medical devices - Part 1: Evaluation and testing.

Device Reuse and Cleaning Validation

The S-Patch ExL can be used on multiple patients. Low-level disinfection is required between patient usage and the low-level disinfection method was satisfactorily evaluated and did not raise any new or different questions of safety or effectiveness.

Electrical Safety and Electromagnetic Compatibility (EMC)

{8}------------------------------------------------

Electrical safety and EMC testing were conducted on the S-Patch ExL. The subject device complies with the electrical safety and electromagnetic compatibility requirements established by the following standards.

StandardsNo.StandardsOrganizationStandard TitleVersion
60601-1AAMI/ANSIMedical Electrical Equipment - Part 1:General Requirements for Basic Safetyand Essential Performance (IEC 60601-1:2005, MOD)ES60601-1-2005(R)2012 andA1:2012
60601-1-2IECMedical Electrical Equipment - Part 1-2:General Requirements for Safety –Collateral Standard: ElectromagneticCompatibility - Requirements and Tests60601-1-2Edition 4.02014-02
60601-1-11IECMedical electrical equipment - Part 1-11:General requirements for basic safety andessential performance - CollateralStandard: Requirements for medicalelectrical equipment and medicalelectrical systems used in the homehealthcare environment60601-1-11Edition 2.02015-01

Firmware/Software Verification and Validation Testing

The S-Patch ExL contains "moderate" level of concern firmware because a failure or latent flaw could lead to a minor injury to the patient through incorrect information or through the action of the healthcare providers. However, the subject device uses the same firmware as the predicate device (K231289). Therefore, no additional firmware/software verification and validation testing was required for this device.

Integration and System Performance Testing

The subject device uses the same firmware as the predicate device (K231289). Therefore, no additional Integration and System Performance Testing was required for this device.

Cybersecurity Assessment and Testing

The subject device uses the same firmware as the predicate device (K231289). Therefore, no additional cybersecurity assessment and Testing were required for this device.

Animal Study

Animal performance testing was not required for this device.

Human Factors Usability Validation Study

A human factors summative usability validation study was conducted, according to FDA's Guidance for Industry and FDA Staff, Applying Human Factors and Usability Engineering to Medical Devices, issued on February 3, 2016. The subject device has the same usage method and similar design as the predicate device (K231289), differing primarily in the

{9}------------------------------------------------

size of the battery side. The change in battery size does not affect the critical tasks of the predicate device and does not introduce new critical tasks.

Clinical Study

Clinical study was not required for demonstrating safety, effectiveness of the subject device and significant equivalence to the predicate device.

{10}------------------------------------------------

10. Conclusion

The subject device S-Patch ExL ECG Patch System is substantially equivalent in indications for use, functions, and performance to the predicate device. The minor difference in battery type between the subject and predicate device was adequately evaluated and did not raise any new or different questions regarding the safety and effectiveness of the device when used as labeled.

The verification and validation testing data supported the substantial equivalence and demonstrated that the subject device performs as intended in the specified use conditions.

Therefore, the S-Patch ExL ECG Patch System is substantially equivalent to the predicate device.

§ 870.2800 Medical magnetic tape recorder.

(a)
Identification. A medical magnetic tape recorder is a device used to record and play back signals from, for example, physiological amplifiers, signal conditioners, or computers.(b)
Classification. Class II (performance standards).